[go: up one dir, main page]

MX2018007782A - Forma cristalina de gemcitabina. - Google Patents

Forma cristalina de gemcitabina.

Info

Publication number
MX2018007782A
MX2018007782A MX2018007782A MX2018007782A MX2018007782A MX 2018007782 A MX2018007782 A MX 2018007782A MX 2018007782 A MX2018007782 A MX 2018007782A MX 2018007782 A MX2018007782 A MX 2018007782A MX 2018007782 A MX2018007782 A MX 2018007782A
Authority
MX
Mexico
Prior art keywords
gemcitabine
crystalline form
alaninyl
benzoxy
phenyl
Prior art date
Application number
MX2018007782A
Other languages
English (en)
Other versions
MX385579B (es
Inventor
Griffith Hugh
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2018007782A publication Critical patent/MX2018007782A/es
Publication of MX385579B publication Critical patent/MX385579B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a una forma cristalina de gemcitabina-[fenil-benzoxi-L-alaninil)]-(S)-fosfato.
MX2018007782A 2015-12-23 2016-12-21 Forma cristalina de gemcitabina. MX385579B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522771.3A GB201522771D0 (en) 2015-12-23 2015-12-23 Crystalline form of a phosphate derivative
PCT/GB2016/054017 WO2017109485A1 (en) 2015-12-23 2016-12-21 Crystalline form of gemcitabine

Publications (2)

Publication Number Publication Date
MX2018007782A true MX2018007782A (es) 2018-08-15
MX385579B MX385579B (es) 2025-03-18

Family

ID=55311540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007782A MX385579B (es) 2015-12-23 2016-12-21 Forma cristalina de gemcitabina.

Country Status (13)

Country Link
US (1) US11377467B2 (es)
EP (1) EP3394077A1 (es)
JP (1) JP6840151B2 (es)
KR (1) KR20180096685A (es)
CN (1) CN108699099A (es)
AU (1) AU2016375860B2 (es)
BR (1) BR112018012943A2 (es)
CA (1) CA3008556A1 (es)
GB (1) GB201522771D0 (es)
HK (1) HK1255112A1 (es)
MX (1) MX385579B (es)
SG (1) SG11201805061YA (es)
WO (1) WO2017109485A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
SI3160978T1 (sl) 2014-06-25 2020-11-30 NuCana plc Gemcitabin predzdravila
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
AU2015411525B2 (en) 2015-10-05 2021-08-12 NuCana plc Combination therapy
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグｎｕｃ−１０３１のジアステレオ選択性合成
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
FR2954310B1 (fr) 2009-12-18 2014-07-25 Univ Rouen Procede de dedoublement d'enantiomeres par evapocristallisation preferentielle
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
WO2014204856A1 (en) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
SI3160978T1 (sl) 2014-06-25 2020-11-30 NuCana plc Gemcitabin predzdravila
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9848863B2 (en) * 2015-02-25 2017-12-26 Globus Medical, Inc Surgical retractor systems and methods
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
AU2015411525B2 (en) 2015-10-05 2021-08-12 NuCana plc Combination therapy
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグｎｕｃ−１０３１のジアステレオ選択性合成
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
PT3393478T (pt) 2015-12-23 2020-03-24 NuCana plc Terapia combinada
WO2018019188A1 (zh) 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法

Also Published As

Publication number Publication date
SG11201805061YA (en) 2018-07-30
US20210188893A1 (en) 2021-06-24
JP6840151B2 (ja) 2021-03-10
US11377467B2 (en) 2022-07-05
GB201522771D0 (en) 2016-02-03
WO2017109485A1 (en) 2017-06-29
EP3394077A1 (en) 2018-10-31
MX385579B (es) 2025-03-18
KR20180096685A (ko) 2018-08-29
CA3008556A1 (en) 2017-06-29
CN108699099A (zh) 2018-10-23
AU2016375860A1 (en) 2018-07-05
BR112018012943A2 (pt) 2018-12-11
AU2016375860B2 (en) 2021-06-03
JP2018538341A (ja) 2018-12-27
HK1255112A1 (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
MX2018007782A (es) Forma cristalina de gemcitabina.
ZA201705776B (en) Crystalline form of nicotinamide riboside
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
EP3119795A4 (en) Gemcitabine analogs
IL258149B (en) Aggregate galnac phosphoramidite
GB201405597D0 (en) Production of cryptographic signatures
GB201609601D0 (en) Phosphoramidate compounds
PL3577125T3 (pl) Postacie krystaliczne alafenamidu tenofowiru
GB201517844D0 (en) Binaural synthesis
HUE054271T2 (hu) Mielóma Multiplex (MM) kezelése
PT3334734T (pt) Forma c de avibactam sódico
IL266087A (en) Use of itolizumab to reduce cd6 phosphorylation
GB2551839B (en) Improvements relating to footwear
EP3393406C0 (en) USE OF SEVERAL BILIAL STENTS
IL274808A (en) Phosphoramidate diphosphate salts of nucleosides as anticancer compounds
EP3207034A4 (en) Anhydrous crystalline form of s-equol
MX2016014255A (es) Producto ceramico refractario.
MX2016012653A (es) Eteraminas basadas en dialcoholes.
MX380240B (es) Preparación de piperidin-4-carbotioamida.
GB2574946B (en) Binaural synthesis
IL271586B1 (en) Ibandronate conjugates of nucleotide antimetabolites
CY1123685T1 (el) Μεθοδος πεγκυλιωσης
GB201711193D0 (en) Novel prodrugs of acyclic nucleoside phosphonates
GB201704577D0 (en) Novel prodrugs of acyclic nucleoside phosphonates
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.